Allan Bruce B, Bell Stacie, Husarek Kathryn
Allan Centre, Calgary, AB, Canada.
Viveve Inc., United States.
Can Urol Assoc J. 2020 Jul;14(7):E313-E318. doi: 10.5489/cuaj.6145.
The purpose of this early feasibility study was to evaluate the safety and efficacy of a non-ablative, cryogen-cooled, monopolar radiofrequency (CMRF) treatment for female stress urinary incontinence (SUI).
Subjects meeting all the inclusion and exclusion criteria were enrolled and randomized into two groups. Subjects in group 1 received one CMRF treatment and subjects in group 2 received two CMRF treatments six weeks apart. Followup visits were performed at one, four, six, and 12 months post-treatment. At each study visit, subjects performed an objective, standardized one-hour pad weight test and completed several patient-reported outcome measures, a seven-day bladder voiding diary, and safety assessments.
Data indicate an improvement in SUI symptoms and quality of life for subjects, as determined by validated SUI-related patient-reported outcomes and the objective one-hour pad weight test, with a >50% reduction in pad weight from baseline for 52% of the subjects at 12 months. In addition to efficacy, the CMRF treatment was well-tolerated and safe.
The outcome measures evaluated indicate an improvement in SUI symptoms and quality of life. The sustained benefit of the CMRF vaginal treatment at 12 months suggests potential use as an office-based, non-surgical approach to treat mild to moderate SUI.
这项早期可行性研究的目的是评估一种非消融性、冷冻剂冷却的单极射频(CMRF)治疗女性压力性尿失禁(SUI)的安全性和有效性。
符合所有纳入和排除标准的受试者被招募并随机分为两组。第1组受试者接受一次CMRF治疗,第2组受试者接受两次CMRF治疗,间隔六周。在治疗后1、4、6和12个月进行随访。在每次研究访视时,受试者进行客观、标准化的一小时尿垫重量测试,并完成多项患者报告的结局指标、一份为期七天的膀胱排尿日记以及安全性评估。
数据表明,根据经过验证的与SUI相关的患者报告结局和客观的一小时尿垫重量测试,受试者的SUI症状和生活质量有所改善,在12个月时,52%的受试者尿垫重量较基线减少了50%以上。除了疗效外,CMRF治疗耐受性良好且安全。
所评估的结局指标表明SUI症状和生活质量有所改善。CMRF阴道治疗在12个月时的持续益处表明其有可能作为一种基于门诊的非手术方法用于治疗轻度至中度SUI。